Feed ATPC
Summary
44 / 100 · Bulios Score
Valuation 99Growth 22Profitability 20Quality 0Debt 100Stability 35
What speaks for it
- The price moves less than the market (beta 0.43).
What to watch
- The company made a loss over the last 12 months.
- Revenue fell by 6.4% a year over the last 3 years.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapThe company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
20212022202320242025
Diluted EPS (USD)
20212022202320242025
Revenue fell by 15% a year over 5 years. Over the last 3 years it fell by 6.4% a year.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $1.14M.
Profitability in detailIs it financially healthy?
Debt is a burdenCash and short-term investments $45.5K
Debt $62.7K
Free cash flow over 12 months -$970.6K
Over the last 12 months it spent more cash than it brought in. Its debt is larger than its cash. The debt score is high even though free cash flow is negative.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 54%
- Product Health Therapies 37%
- Health and Wellness Services 6.8%
- Energized Mineral Concentrate 2.4%
By region
The company reports no revenue by region.
Product brings in 54% of revenue.
Segments in detail